Clinical Trials

Expanded Access Policy

ALX Oncology is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The goal of our current clinical study program is to enroll patients and obtain clinical data on our investigational drugs that is required by the U.S. Food and Drug Administration (FDA) and other regulatory authorities for review and approval of marketing applications for these investigational agents.

We believe that focusing on clinical studies is the most appropriate way to achieve this goal; therefore, we do not currently offer access to our investigational drugs outside of clinical studies and, at this time, we have no Expanded Access Programs (sometimes referred to as "compassionate use" or "pre-approval access").
If you have additional questions regarding this policy, please speak with your healthcare provider or contact: medinfo@alxoncology.com